Related Experiment Video
Updated: Aug 11, 2025
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy
Sara Jaber1, Marine Warnier1, Christopher Leers1
1Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.
Abstract:
Pancreatic cancer is one of the deadliest cancers owing to its late diagnosis and of the strong resistance to available treatments. Despite a better understanding of the disease in the last two decades, no significant improvement in patient care has been made. Senescent cells are characterized by a stable proliferation arrest and some resistance to cell death. Increasing evidence suggests that multiple lines of antitumor therapy can induce a senescent-like phenotype in cancer cells, which may participate in treatment resistance. In this study, we describe that gemcitabine, a clinically-used drug against pancreatic cancer, induces a senescent-like phenotype in highly chemoresistant pancreatic cancer cells in vitro and in xenografted tumors in vivo. The use of ABT-263, a well-described senolytic compound targeting Bcl2 anti-apoptotic proteins, killed pancreatic gemcitabine-treated senescent-like cancer cells in vitro. In vivo, the combination of gemcitabine and ABT-263 decreased tumor growth, whereas their individual administration had no effect. Together these data highlight the possibility of improving the efficacy of conventional chemotherapies against pancreatic cancer by eliminating senescent-like cancer cells through senolytic intervention. Further studies testing different senolytics or their combination with available treatments will be necessary to optimize preclinical data in mouse models before transferring these findings to clinical trials.
Insights
Gemcitabine causes pancreatic cancer cells to enter a senescent-like state, resisting treatment. Combining gemcitabine with the senolytic drug ABT-263 effectively reduced tumor growth in preclinical models.
Area of Science:
- Oncology
- Cell Biology
- Cancer Therapeutics
Background:
- Pancreatic cancer has a poor prognosis due to late diagnosis and treatment resistance.
- Therapies can induce a senescent-like phenotype in cancer cells, contributing to resistance.
- Senescent cells exhibit stable proliferation arrest and resistance to apoptosis.
Purpose of the Study:
- To investigate if gemcitabine induces a senescent-like phenotype in pancreatic cancer cells.
- To evaluate the efficacy of senolytic treatment in combination with gemcitabine.
- To explore novel therapeutic strategies for chemoresistant pancreatic cancer.
Main Methods:
- Gemcitabine treatment of pancreatic cancer cells in vitro and in vivo xenografts.
- Assessment of gemcitabine-induced senescent-like phenotype.
- Treatment with ABT-263, a senolytic drug targeting Bcl2 proteins.
- Combination therapy of gemcitabine and ABT-263 in vivo.
Main Results:
- Gemcitabine induced a senescent-like phenotype in chemoresistant pancreatic cancer cells.
- The senolytic compound ABT-263 eliminated gemcitabine-induced senescent-like cells in vitro.
- Combination therapy of gemcitabine and ABT-263 significantly decreased tumor growth in vivo.
- Individual administration of gemcitabine or ABT-263 showed no significant effect on tumor growth.
Conclusions:
- Eliminating senescent-like cells can enhance the efficacy of conventional chemotherapy for pancreatic cancer.
- Senolytic intervention represents a promising strategy to overcome treatment resistance in pancreatic cancer.
- Further preclinical studies are needed to optimize senolytic combinations for clinical trials.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...